Mereo Biopharma Group PLC

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Mereo Biopharma Group PLC
TickerMREO
CIK #0001719714
CUSIP589492107
SectorLife Sciences - Pharmaceutical Preparations
AddressOne Cavendish Place Fourth Floor, London, W1G0QF
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Mereo Biopharma Group PLC 2020-06-12 70.0 M Exemption: 506(b) · Minimum: $1 · Duration: One year or less · Commission: $4,200,000 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001719714] 10-K
[0001719714] 10-Q
[0001719714] 3
[0001719714] 4
[0001719714] 6-K
[0001719714] 8-K
[0001719714] D
[0001719714] SC 13D
[0001719714] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Bank of America Corp /DE/ Mereo Biopharma Group PLC [2026-05-14] 0.0
EcoR1 Capital LLC Mereo Biopharma Group PLC [2026-01-09] 0.0
683 Capital Management LLC Mereo Biopharma Group PLC [2026-01-06] 0.0
Northpond Ventures LP Mereo Biopharma Group PLC [2025-06-11] 0.0
Frazier Life Sciences Public Fund LP Mereo Biopharma Group PLC [2025-04-04] 0.0
Janus Henderson Group PLC Mereo Biopharma Group PLC [2024-07-11] 5.2
Mangrove Partners IM LLC Mereo Biopharma Group PLC [2024-02-14] 6.24
Adage Capital Partners GP LLC Mereo Biopharma Group PLC [2024-02-05] 7.17
Soleus Private Equity Fund III LP Mereo Biopharma Group PLC [2023-07-26] 2.8
Rubric Capital Management LP Mereo Biopharma Group PLC [2022-05-26] 12.82
Rock Springs Capital Management LP Mereo Biopharma Group PLC [2022-02-15] 5.13
Rubric Capital Management LP Mereo Biopharma Group PLC [2021-12-02] 10.38
Point72 Asset Management LP Mereo Biopharma Group PLC [2021-03-01] 6.4
Suvretta Capital Management LLC Mereo Biopharma Group PLC [2021-02-19] 5.9
Baker Bros Advisors LP Mereo Biopharma Group PLC [2021-02-16] 11.4
OrbiMed Advisors LLC Mereo Biopharma Group PLC [2021-02-12] 5.33
Citadel Advisors LLC Mereo Biopharma Group PLC [2020-07-10] 8.9
Aspire Capital Fund LLC Mereo Biopharma Group PLC [2020-07-02] 6.11
Vivo Capital IX LLC Mereo Biopharma Group PLC [2020-06-12] 1.5
BlackRock Inc Mereo Biopharma Group PLC [2020-03-09] 13.2
Boxer Capital LLC Mereo Biopharma Group PLC [2020-03-02] 0.0
Mereo Biopharma Group PLC OncoMed Pharmaceuticals Inc [2018-12-17] 10.7
Form 3/4/5 Filer 2011 - 2026
Mereo BioPharma Group PLC
Jacquet Pierre
Yoskowitz Marc J
Shames Daniel
Ekblom Anders
Pakianathan Deepika
Wyzga Michael S
Bender Jeremy
Jenkins Annalisa
Lewicki John A
Hughes-Wilson Alexandra
Sermon Charles
Scots-Knight Denise
Fox Christine Ann
Rosen David Efraim
Rubric Capital Management LP
Roberts Justin Hunter
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Yoskowitz Marc J
Share Options (Right to buy) · derivative
2026-02-26 Grant 66,000 $0.00
Yoskowitz Marc J
Deferred Restricted Stock Units · derivative
2026-02-26 Grant 96,163
Jacquet Pierre
Share Options (Right to buy) · derivative
2026-02-26 Grant 66,000 $0.00
Jacquet Pierre
Deferred Restricted Stock Units · derivative
2026-02-26 Grant 106,848
Jenkins Annalisa
Share Options (Right to buy) · derivative
2026-02-26 Grant 66,000 $0.00
Jenkins Annalisa
Deferred Restricted Stock Units · derivative
2026-02-26 Grant 106,848
Shames Daniel
Share Options (Right to buy) · derivative
2026-02-26 Grant 66,000 $0.00
Shames Daniel
Deferred Restricted Stock Units · derivative
2026-02-26 Grant 96,163
Bender Jeremy
Deferred Restricted Stock Units · derivative
2026-02-26 Grant 117,533
Ekblom Anders
Share Options (Right to buy) · derivative
2026-02-26 Grant 66,000 $0.00
Ekblom Anders
Deferred Restricted Stock Units · derivative
2026-02-26 Grant 133,560
Bender Jeremy
Share Options (Right to buy) · derivative
2026-02-26 Grant 66,000 $0.00
Pakianathan Deepika
Share Options (Right to buy) · derivative
2026-02-26 Grant 66,000 $0.00
Wyzga Michael S
Share Options (Right to buy) · derivative
2026-02-26 Grant 66,000 $0.00
Lewicki John A
Share Options (Right to buy) · derivative
2026-02-01 Grant 46,637 $0.00
Lewicki John A
Share Options (Right to buy) · derivative
2026-02-01 Grant 139,913 $0.00
Lewicki John A
Share Options (Right to buy) · derivative
2026-02-01 Grant 145,000 $0.00
Hughes-Wilson Alexandra
Share Options (Right to buy) · derivative
2026-02-01 Grant 61,250 $0.00
Hughes-Wilson Alexandra
Share Options (Right to buy) · derivative
2026-02-01 Grant 183,750 $0.00
Hughes-Wilson Alexandra
Share Options (Right to buy) · derivative
2026-02-01 Grant 195,000 $0.00
showing 20 of 139 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 64 76,277,137
2025-12-31 74 66,742,428
2025-09-30 87 102,452,945
2025-06-30 90 101,585,985
2025-03-31 91 112,769,972
2024-12-31 92 115,754,824
2024-09-30 78 106,115,993
2024-06-30 80 100,617,222
2024-03-31 81 87,260,767
2023-12-31 66 78,989,124
2023-09-30 57 70,648,060
2023-06-30 55 64,825,061
Form 13F Holdings
Firm Period DFND Voting Shares
Significant Wealth Partners LLC [2026-06-30] SOLE 0 32,677
Gamma Investing LLC [2026-06-30] DFND 9,308 9,308
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com